Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.
Three patients with diffuse large B-cell type of post-transplant lymphoproliferative disease after lung transplantation were treated with rituximab, an anti-CD20 monoclonal antibody. Treatment resulted in two complete remissions and one non-response.
Cook
R C
RC
Connors
J M
JM
Gascoyne
R D
RD
Fradet
G
G
Levy
R D
RD
D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D016040:Lung Transplantation; D008207:Lymphatic Metastasis; D016393:Lymphoma, B-Cell / Q000000981:diagnostic imaging / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D011183:Postoperative Complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011859:Radiography; D012074:Remission Induction; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab